- Home
- OFS vs PMVP Comparison
OFS vs PMVP Comparison
Compare OFS & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFS | PMVP |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | United States |
| Employees | 53 | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 59.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OFS | PMVP |
|---|---|---|
| Price | $4.31 | $1.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 88.9K | ★ 319.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 15.42% | N/A |
| EPS Growth | N/A | ★ 20.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.98 | $0.82 |
| 52 Week High | $9.80 | $1.84 |
Technical Indicators
Market Signals| Indicator | OFS | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 45.53 | 79.57 |
| Support Level | N/A | $1.32 |
| Resistance Level | $5.33 | $1.84 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 53.21 | 96.21 |
Price Performance
Historical ComparisonAbout OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.